Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Mutual Reliance with EU on Inspections Is Slow Going

This article was originally published in The Gold Sheet

Executive Summary

FDA still does over 40% of its inspections in Europe even as it acknowledges it must spend the money elsewhere.

You may also be interested in...



Despite Globalization, Three Quarters of Serious Inspection Issues FDA Found Were in US

Interactive map, charts provide details on our analysis of FDA 2009-2014 inspection results data showing that even as the agency responded to the threat of poor drug quality abroad, it was more successful at finding serious quality issues during its much more numerous domestic inspections.

Despite Globalization, Three Quarters of Serious Issues FDA Found Were in US

FDA inspection results data show that even as the agency responded to the threat of poor drug quality abroad in fiscal years 2009-2014, it was more successful at finding serious quality issues during its much more numerous domestic inspections. Asian inspections were somewhat more likely to identify serious issues than US ones, while European inspections were much less likely to raise any, and neither identified nearly as many.

FDA Globalization Capacity, Shortage Monitoring Remain Concerns, GAO Says

In updated high-risk report, GAO says resources are an issue for FDA’s globalization plans and the agency should better manage its drug shortage data.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS000883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel